ERJ Open Research最新文献

{"title":"Diagnostic, prognostic, and therapeutic challenges in patients with hypersensitivity pneumonitis.","authors":"Anna Papasarantou, Vasilios Tzilas, Konstantinos Loverdos, Foteini Karakontaki, Ourania Papaioannou, Eleni Stagaki, Evangelia Koukaki, Nektarios Anagnostopoulos, Grigorios Stratakos, Theodoros Karampitsakos","doi":"10.1183/23120541.00424-2026","DOIUrl":"10.1183/23120541.00424-2026","url":null,"abstract":"<p><p>Hypersensitivity pneumonitis is an immune-mediated lung disease resulting from prolonged and/or repeated exposure to an inciting antigen. The official American Thoracic Society (ATS)/Japanese Respiratory Society/Latin American Thoracic Association clinical practice guideline for the diagnosis of hypersensitivity pneumonitis in adults and the European Respiratory Society/ATS statement for the update of the international multidisciplinary classification of the interstitial pneumonias represented a major step to reduce diagnostic uncertainty among clinicians. However, the diagnosis of hypersensitivity pneumonitis remains sometimes challenging due to the variability in clinical, radiological and pathological manifestations of hypersensitivity pneumonitis. Diagnostic challenges include the timely identification of the inciting antigen, the proper execution and interpretation of high-resolution computed tomography, the absence of a disease-specific, clinically applicable feature in bronchoalveolar lavage, the limited access to cryobiopsy in some centres, and the lack of pathognomonic findings at the clinical, imaging and pathology level. Accordingly, prognostic challenges also exist and include the clinical applicability of disease-specific biomarkers. In terms of treatment, there is a pressing need for studies aiming to identify endotypes that are more likely to benefit from immunomodulation, antifibrotics or a combination of both. This review article aims to present diagnostic, prognostic and therapeutic challenges in patients with hypersensitivity pneumonitis and highlight future perspectives in the field.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emphysema Severity Index: a new spirometric parameter in epidemiology.","authors":"Sara Maio, Giovanni Viegi, Laura Carrozzi, Sandra Baldacci, Giuseppe Sarno, Anna Angino, Ilaria Stanisci, Sofia Tagliaferro, Patrizia Silvi, Giovanni Cenerini, Michele Paladina, Maria Elena Occhipinti, Matteo Paoletti, Massimo Pistolesi, Francesco Pistelli","doi":"10.1183/23120541.01587-2025","DOIUrl":"10.1183/23120541.01587-2025","url":null,"abstract":"<p><strong>Background: </strong>The Emphysema Severity Index (ESI) is a recently developed parameter describing the curvilinear shape of the expiratory flow/volume curve to evaluate the emphysema contribution to airflow obstruction (AO), as observed in COPD patients and geriatric populations. The aim of the present study was to assess ESI usefulness in respiratory epidemiology studies where spirometry is typically the only available objective tool.</p><p><strong>Methods: </strong>An adult population sample of Pisa (Central Italy) (n=685, 47.3% male, mean age 53.3 years) participated in an epidemiological survey through standardised questionnaire and spirometry (2009-2011); information on hospital admissions was available up to 2017. The input variables for the ESI computing algorithm are peak expiratory flow, forced vital capacity (FVC) and the forced expiratory flows at 25%, 50% and 75% of FVC. ESI is a numerical value ranging from 0 (no emphysema) to 10 (very severe emphysema). Statistics included descriptive analyses, Kruskas-Wallis nonparametric test and logistic regression models.</p><p><strong>Results: </strong>The ESI mean±sd value was: 1.16±0.78; median (IQR) 0.98 (0.39). The ESI was significantly higher in males, ex-smokers, the elderly, subjects with asthma/COPD, and in those with limited daily activities, higher number of doctor visits and hospital admission for respiratory disease. For each increment of an ESI IQR, higher odds of respiratory outcomes, daily activity limitations and use of health services emerged in the total sample, but also in subjects without AO.</p><p><strong>Conclusions: </strong>ESI represents a potentially valuable indicator in epidemiological surveys on the general population and allows early changes in lung function to be identified also in subjects without AO, which is valuable for secondary prevention.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the General Practice Physical Activity Questionnaire after severe COVID-19.","authors":"Lin Wang, Kimon Ntotsis, James Manifield, Katerina Tziannou, Tatiana Plekhanova, Alex Rowlands, Charlotte L Edwardson, Molly Baldwin, Nicolette C Bishop, Charlotte Bolton, James D Chalmers, Enya Daynes, Annemarie Docherty, Claudia Efstathiou, Omer Elneima, Lucy Gardiner, William Greenhalf, Neil Greening, Beatriz Guillen-Guio, Victoria Harris, Ewen Harrison, Ling-Pei Ho, Alexander Horsley, Linzy Houchen-Wolloff, Joseph Jacob, Olivia Leavy, Nazir Lone, Daniel Lozano-Rojas, Michael Marks, Hamish McAuley, Melitta McNarry, Claire Nolan, Jennifer K Quint, Betty Raman, Matthew Richardson, Jack Sargeant, Ruth M Saunders, Marco Sereno, Aarti Shikotra, Amisha Singapuri, David J Stensel, Maxime Taquet, Mathew Thorpe, Ioannis Vogiatzis, William Man, Louise V Wain, Iain Stewart, Sally Singh, Christopher E Brightling, Claire Lawson, Tom Yates, Rachael A Evans","doi":"10.1183/23120541.01496-2025","DOIUrl":"10.1183/23120541.01496-2025","url":null,"abstract":"<p><strong>Background: </strong>Physical inactivity is a risk factor for severe COVID-19 and often worsens after hospitalisation. Clinicians need quick, accurate assessments to target interventions. We aimed to assess the validity of the General Practice Physical Activity Questionnaire (GPPAQ) in adults recovering 1 year after COVID-19 hospitalisation<b>.</b></p><p><strong>Methods: </strong>Post-hospitalisation for COVID-19, adults attended a 1-year-visit and completed the GPPAQ Physical Activity Index (PAI-4 active), 14-day wrist-worn accelerometry (moderate-vigorous physical activity (MVPA) active) and other health outcomes. Validity was examined <i>via</i> 1) internal consistency (factor analysis); 2) measurement invariance across sex, age and ethnicity using differential item functioning (DIF); 3) convergent validity (GPPAQ sensitivity/specificity <i>versus</i> accelerometry); and 4) construct validity (correlations with health outcomes).</p><p><strong>Results: </strong>752 participants had GPPAQ and accelerometry (265 female, mean±sd age 60.9±11.6 years), MVPA 18.75 min·day^-1 (interquartile range 7.55-36.11), PAI-1 46.8%, PAI-2 15.6%, PAI-3 19.4% and PAI-4 18.2%. Factor analyses supported good internal consistency with two factors (daily activities and physical exercise). Comparative factor index (CFI) showed an excellent fit (CFI 0.965). DIF indicated moderate variability by sex and age. GPPAQ-PAI showed limited sensitivity (26.3%) for correctly classifying physically active individuals, but higher specificity (88.4%) for classifying physical inactivity, and weak-to-moderate correlations with health outcomes.</p><p><strong>Conclusions: </strong>GPPAQ demonstrates internal consistency, with construct and convergent validity in adults 1 year after COVID-19 hospitalisation. GPPAQ effectively identifies inactive individuals to support clinical care; however, its sensitivity suggests under-estimation of activity relative to accelerometry. Future pathways should combine GPPAQ with device-based assessment to optimise evaluation of physical activity to guide pulmonary rehabilitation and targeted interventions.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of allergic bronchopulmonary aspergillosis overlap in chronic pulmonary aspergillosis.","authors":"Ana Raquel Afonso, Dareen Marghlani, Mohammed Alramadhan, Aran Singanayagam, Melody Ni, Darius Armstrong-James, Anand Shah","doi":"10.1183/23120541.01540-2025","DOIUrl":"10.1183/23120541.01540-2025","url":null,"abstract":"<p><strong>Background: </strong>Chronic pulmonary aspergillosis (CPA) is a destructive fungal infection caused by <i>Aspergillus fumigatus</i>, leading to significant morbidity in individuals with structural lung disease. Clinical and immunological overlap with allergic bronchopulmonary aspergillosis (ABPA) has been recognised, but its extent and prognostic relevance remain uncertain. This study assessed ABPA features in CPA and their relationship with immunological markers and long-term outcome.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study including individuals with confirmed CPA at the Royal Brompton Hospital until December 2023. Diagnoses followed ERS/ESCMID and 2024 ISHAM criteria. Demographic, clinical, microbiological and immunological data were analysed, and group comparisons performed using logistic regression and Cox proportional hazards models.</p><p><strong>Results: </strong>Among 166 individuals with CPA, 45 (27%) met ABPA diagnostic criteria. CPA/ABPA overlap was independently associated with asthma (OR 10.16) and pan-azole resistance (OR 19.37), and inversely with sarcoidosis (OR 0.22). Overall 5-year survival was 82% (84.6% in CPA alone <i>versus</i> 76.6% in overlap; p=0.44). Older age, lower body mass index and albumin, and elevated <i>A. fumigatus</i>-specific IgE and IgG were associated with higher mortality, while longitudinal increase in <i>A. fumigatus</i>-specific IgE was also linked to worse outcome. Low serum albumin independently predicted mortality (HR 0.72; p=0.001).</p><p><strong>Discussion: </strong>CPA/ABPA overlap represents a distinct clinical phenotype linked to airway disease, antifungal resistance and Th2-driven inflammation. Nutritional status and immunological activity, particularly rising <i>A. fumigatus</i>-specific IgE, emerged as key prognostic markers, linking type 2 inflammation to disease progression. These findings highlight the need for phenotype-based risk stratification and exploration of targeted immunomodulatory strategies in CPA.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of hypertonic saline and/or carbocisteine on sputum rheology in bronchiectasis: CLEAR-EME.","authors":"Michael C McKelvey, Gisli G Einarsson, Jack Carson, Aram Kadoom, Ryan R Brown, Christina Campbell, Andrew Jackson, Cliona McDowell, Mike Clarke, Fiona Copeland, Kathryn Ferguson, Rebecca H McLeese, Rory Convery, Adam T Hill, Anthony De Soyza, Mitra Shahidi, Martin Kelly, Mary Carroll, Timothy Gatheral, Muhammed Anwar, Jamie Duckers, William Flight, John R Hurst, A Alina Ionescu, Michael R Loebinger, Anita L Sullivan, James D Chalmers, Damian G Downey, Michael M Tunney, Brenda O'Neill, Daniel F McAuley, J Stuart Elborn, Judy M Bradley, Clifford C Taggart","doi":"10.1183/23120541.00202-2026","DOIUrl":"10.1183/23120541.00202-2026","url":null,"abstract":"<p><strong>Background: </strong>Mucoactives such as hypertonic saline (HTS) and carbocisteine are widely used in the treatment of bronchiectasis, though there is insufficient evidence to support their use. The aim of this mechanistic sub-study, embedded within the CLEAR trial, was to characterise the properties of sputum from patients with bronchiectasis and to assess whether treatment with HTS and/or carbocisteine altered these properties.</p><p><strong>Methods: </strong>In CLEAR, patients were randomised to receive HTS, carbocisteine, HTS plus carbocisteine or standard care, and sputum samples were collected at randomisation (baseline) and at 2 and 8 weeks post-randomisation. Sputum viscoelasticity was determined by rotational plate rheometry. Biomarkers were quantified by ELISA and microbiome composition was assessed by next-generation sequencing. The primary outcome was differences in sputum viscoelasticity between groups at 2 weeks following the commencement of treatment.</p><p><strong>Results: </strong>Sputum viscoelastic properties were not reduced by 2 or 8 weeks of treatment with HTS and/or carbocisteine (n=6-15 per group). Sputum biomarker levels and bacterial community composition were similar across groups at 2 or 8 weeks. At baseline, viscoelasticity (crossover point σ_c) was positively correlated with interleukin-8 (r=0.49, p=0.012) and greater relative bacterial dominance (r=0.35, p=0.041).</p><p><strong>Conclusions: </strong>These data do not support the use of HTS or carbocisteine to alter sputum viscoelasticity, inflammatory marker levels or bacterial community composition in patients with bronchiectasis.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoimmune pulmonary alveolar proteinosis may not be invariably lifelong: exponential decay of anti-granulocyte-macrophage colony-stimulating factor autoantibodies over more than a decade.","authors":"Sinya Ohkouchi, Ryushi Tazawa, Takahiro Tanaka, Nobutaka Kitamura, Haruyuki Ishii, Koh Nakata","doi":"10.1183/23120541.00345-2026","DOIUrl":"10.1183/23120541.00345-2026","url":null,"abstract":"<p><p><b>aPAP may not be lifelong: in three long-term cases, anti-GM-CSF autoantibodies peaked early then declined with exponential kinetics, disappearing after 7-16 years, suggesting eventual immune quiescence <i>via</i> attrition of long-lived plasma cells</b> https://bit.ly/4n2m9No.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Budesonide/formoterol fumarate dihydrate <i>versus</i> budesonide with a novel suspension technology for uncontrolled asthma: phase 3 VATHOS study.","authors":"David J Jackson, Robert A Wise, Alberto Papi, Njira Lugogo, Ruchong Chen, Hassan Chami, Clara Armengol, Sami Z Daoud, Emma Nauclér, Karin Bowen, Ayman Megally, Olami Sobande, Mehul Patel","doi":"10.1183/23120541.01817-2025","DOIUrl":"10.1183/23120541.01817-2025","url":null,"abstract":"<p><strong>Background: </strong>Inhaled corticosteroid (ICS)/long-acting β₂-agonist (LABA) therapy is important in asthma. The phase 3 VATHOS study (ClinicalTrials.gov: NCT05202262) assessed the efficacy and safety of budesonide/formoterol fumarate dihydrate (BFF) <i>via</i> metered-dose inhaler (MDI) using Aerosphere co-suspension technology (BFF_A) <i>versus</i> either budesonide (BD) <i>via</i> MDI using Aerosphere or BFF <i>via</i> dry-powder inhaler (BFF_DPI).</p><p><strong>Methods: </strong>Participants (age 12-80 years; n=645) with inadequately controlled asthma on medium-dose ICS or ICS/LABA were randomised 1:2:2:2 to twice-daily BFF 160/10 μg (BFF_A 160), BFF 320/10 μg (BFF_A 320), BD 320 μg (BD 320) or open-label BFF_DPI 320/9 μg, respectively. End-points included change from baseline in forced expiratory volume in 1 s area under the curve from 0 to 3 h (FEV₁ AUC_0-3) at 24 weeks (primary), and morning pre-dose trough FEV₁ at 24 weeks, onset of action (day 1 change in FEV₁, 5 min post-dose) and severe exacerbation rates (secondary). Adverse events (AEs) were recorded.</p><p><strong>Results: </strong>BFF_A 320 demonstrated superior lung function <i>versus</i> BD 320 at week 24 (mean change from baseline in FEV₁ AUC_0-3: 173 (95% CI 112-233) mL (p<0.0001); trough FEV₁: 61 (95% CI 1-120) mL (p=0.0447); onset of action: 144 (95% CI 110-177) mL (p<0.0001)). Severe exacerbation rates were similar between BFF_A 320 and BD 320 (rate ratio 1.02 (95% CI 0.61-1.70); p=0.9473). AEs were similar across treatments (BFF_A 320, 50.3%; BFF_A 160, 50.0%; BD 320, 38.1%; BFF_DPI, 45.7%). BFF_A 320 showed non-inferiority to BFF_DPI in lung function.</p><p><strong>Conclusion: </strong>These findings support the use of BFF_A 320 with co-suspension delivery technology in people with inadequately controlled asthma on medium-dose ICS or ICS/LABA.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13573227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148967244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Budesonide/formoterol fumarate dihydrate <i>versus</i> budesonide with a novel suspension technology for uncontrolled asthma: phase 3 LITHOS study.","authors":"Alberto Papi, Robert A Wise, David J Jackson, Njira Lugogo, Ruchong Chen, Hassan Chami, Clara Armengol, Sami Z Daoud, Emma Nauclér, Karin Bowen, Ayman Megally, Olami Sobande, Mehul Patel","doi":"10.1183/23120541.01818-2025","DOIUrl":"10.1183/23120541.01818-2025","url":null,"abstract":"<p><strong>Background: </strong>Inhaled corticosteroid (ICS)/long-acting β₂-agonist (LABA) therapy is a mainstay asthma treatment. LITHOS (clinicaltrials.gov identifier NCT05755906), a randomised phase 3 study, assessed efficacy and safety of low-dose budesonide/formoterol fumarate dihydrate (BFF) <i>via</i> a metered-dose inhaler (MDI) using Aerosphere co-suspension delivery technology (BFF_A) <i>versus</i> low-dose budesonide <i>via</i> MDI using Aerosphere (BD).</p><p><strong>Methods: </strong>Participants (aged 12-80 years; N=374) with inadequately controlled asthma (seven-item Asthma Control Questionnaire score ≥1.5) despite low-dose ICS or ICS/LABA were randomised to 12 weeks of twice-daily BFF 160/10 μg (BFF_A 160) or BD 160 μg (BD 160). End-points included change from baseline in forced expiratory volume in 1 s (FEV₁) area under the curve from 0-3 h (AUC_0-3) (primary) and morning pre-dose trough FEV₁ (key secondary) at week 12, onset of action, severe exacerbation rates and safety/tolerability.</p><p><strong>Results: </strong>Least-square mean differences (95% CI) demonstrated that BFF_A 160 provided superior lung function improvement <i>versus</i> BD 160 at week 12 for change from baseline in FEV₁ AUC_0-3 (200 (134-267) mL; p<0.0001) and morning pre-dose FEV₁ (82 (20-144) mL; p=0.0096). Severe exacerbation rates were nominally reduced with BFF_A 160 <i>versus</i> BD 160 (rate ratio (95% CI) 0.48 (0.23-0.97); unadjusted p=0.0419). No new or unexpected safety findings were observed; on-treatment adverse effects were comparable between treatments (BFF_A 160, 18.4%; BD 160, 19.5%).</p><p><strong>Conclusion: </strong>These findings support the use of BFF_A 160 twice daily with novel Aerosphere technology for the treatment of people aged 12-80 years with asthma inadequately controlled by low-dose ICS or ICS/LABA.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13573226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148967290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endpoints in cough studies: learnings from the ERS Cough Conference.","authors":"Alyn H Morice","doi":"10.1183/23120541.01190-2026","DOIUrl":"10.1183/23120541.01190-2026","url":null,"abstract":"<p><p><b>Single-day average cough counting is the wrong endpoint to use in cough trials</b> https://bit.ly/3UgsKcB.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13573219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148967296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asthma remission following inhaled treatments.","authors":"Dennis Thomas, Peter G Gibson","doi":"10.1183/23120541.00799-2026","DOIUrl":"10.1183/23120541.00799-2026","url":null,"abstract":"<p><p><b>Asthma remission is an attainable goal across severities, endotypes and treatments. Optimised inhaled therapy can induce remission in over a quarter of patients, with triple therapy outperforming dual therapy.</b> https://bit.ly/4xkFUEs.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13573215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148967215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}